london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

The efficacy of intravitreal ranibizumab treatment in diabetic macular edema

Poster Details

First Author: E.Esen TURKEY

Co Author(s):    S. Sizmaz   G. Simdivar   N. Demircan            0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the outcomes of intravitreal ranibizumab injection in the treatment of diabetic macular edema (DME), to investigate the factors that may affect the efficacy of the treatment.

Setting:

Cukurova University, Faculty of Medicine, Department of Ophthalmology, Adana, Turkey.

Methods:

The patients with DME who were treated with intravitreal ranibizumab injection were enrolled in the study. The demographic characteristics, duration of diabetes, antidiabetic medication, hemoglobin A1c value, previous treatment for DME were recorded; diabetic retinopathy stage was evaluated on the fluorescein angiography. The best corrected visual acuity (BCVA) and santral macular thickness (SMT) measured before and at the last visit were compared. The effectiveness of the treatment was studied, the association between aforementioned factors and the change in BCVA and SMT was investigated.

Results:

In the study 65 eyes of 41 patients were studied. The mean follow-up was 9,38±3 (6-18) months, the mean number of injections was 3,7±1,04 (1-6). Before the injections and at the last visit the mean logMAR BCVA was 0,88±0,38 (0,1-1,8) and 0,62±0,4 (0-1,8), the mean SMT was 391,63±84,67 (254-733) µm and 291,89±113,65 (130-695) µm respectively. The difference in visual acuity and SMT were statistically significant. There was no statistically significant corelation between the factors mentioned above and the difference in BCVA and SMT.

Conclusions:

Intravitreal injection of ranibizumab in DME is an effective treatment that provides increase in visual acuity and decrease in SMT. The effectiveness of the treatment differs among patients. There are numerous factors that may cause this difference. Larger number of patients and longer follow-up time is required to detect these factors which may affect anatomical and functional success of the treatment.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy